Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07112872) titled 'A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Hoffmann-La Roche
Condition:
Type 2 Diabetes Mellitus
Intervention:
Drug: RO7795081
Drug: Semaglutide
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: August 31, 2025
Target Sample Size: 240
Countries of Recruitment:
United States
To know more, visit https://clinicalt...